Disease · MONDO_0006325
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Cabozantinib-s-malate) vs Arm II (Temozolomide or Dacarbazine): Confirmed Response Rate as Determined by the RECIST Criteria (Version 1.1) | 0 of 31 | 0 of 15 | 46 | NCT01835145 | Trial comparisons |
| Cells + High Dose Aldesleukin vs Cells and no High Dose Aldesleukin: Count of Participants With Changes in Visual Symptoms | 1 of 22 | 0 of 2 | 24 | NCT01814046 | Trial comparisons |
Cells + High Dose Aldesleukin vs Cells and no High Dose Aldesleukin: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | 22 of 22 | 2 of 2 | 24 | NCT01814046 | Trial comparisons |
| Cohort 1 - 25 mg Lenalidomide (Revlimid) vs Cohort 2 - 5 mg Lenalidomide (Revlimid): Number of Participants With Adverse Events | 8 of 8 | 9 of 9 | 17 | NCT00109005 | Trial comparisons |
| Cohort 1 - 25 mg Lenalidomide (Revlimid) vs Cohort 2 - 5 mg Lenalidomide (Revlimid): serious adverse events | 1 of 8 | 1 of 9 | 17 | NCT00109005 | Trial comparisons |
| Cohort 1-lenalidomide & Cyclophosphamide vs Cohort 2-sunitinib & Cyclophosphamide: Toxicity | 3 of 3 | 8 of 9 | 12 | NCT00482911 | Trial comparisons |
| Cohort 1-lenalidomide & Cyclophosphamide vs Cohort 2-sunitinib & Cyclophosphamide: serious adverse events | 0 of 3 | 2 of 9 | 12 | NCT00482911 | Trial comparisons |
| Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: Objective Response Rate (ORR) | 1 of 1 | 1 of 3 | 4 | NCT03850691 | Trial comparisons |
| Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: Safety and Tolerability of Sequential Combination Immunotherapy (Incidence of Stopping Rule Events) | 0 of 1 | 0 of 3 | 4 | NCT03850691 | Trial comparisons |
| Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: deaths from any cause | 1 of 1 | 2 of 3 | 4 | NCT03850691 | Trial comparisons |
| Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: serious adverse events | 1 of 1 | 0 of 3 | 4 | NCT03850691 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006325/comparisons